Moving toward a more ideal anticoagulant: The oral direct thrombin and factor Xa inhibitors

Chest

Volumn 143, Issue 4, 2013, Pages 1106-1116

  King, Christopher S ^a   Holley, Aaron B ^b   Moores, Lisa K ^c  

^a Pulmonary and Critical Care Medicine   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; HEPARIN; HIRULOG; KETOCONAZOLE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN C; PROTEIN S; PROTEINASE INHIBITOR; PROTHROMBIN; PYRROLE; QUINIDINE; RIFAMPICIN; RIVAROXABAN; UNINDEXED DRUG; VERAPAMIL; VON WILLEBRAND FACTOR;

ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CANADA; CEREBROVASCULAR ACCIDENT; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EUROPE; HEART ATRIUM FIBRILLATION; HUMAN; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; SECONDARY PREVENTION; STEADY STATE; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84875977824     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1362     Document Type: Article

References (84)

1. Tsiara S, Pappas K, Boutsis D, Laffan M. New oral anticoagulants: should they replace heparins and warfarin? Hellenic J Cardiol. 2011 ; 52 (1): 52-67.
2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G ; American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2): e44S-e88S.
3. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008 ; 25 (1): 52-60.
4. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005 ; 353 (10): 1028-1040.
5. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology. 2011 ; 43 (7): 682-692.
6. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990 ; 86 (2): 385-391.
7. Cheng JW, Vu H. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. Clin Ther. 2012 ; 34 (4): 766-787.
8. Maegdefessel L, Spin JM, Azuma J, Tsao PS. New options with dabigatran etexilate in anticoagulant therapy. Vasc Health Risk Manag. 2010 ; 6 : 339-349.
9. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008 ; 36 (2): 386-399.
10. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dab igatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007 ; 64 (3): 292-303.
11. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008 ; 47 (1): 47-59.
12. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etex ilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008; 48(12): 1411-1419.
13. Legrand MMJ, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011; 171(14): 1285-1286.
14. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol. 2011 ; 155 (2): 137-149.
15. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 ; 45 (5): 555-563.
16. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012 ; 26 (1): 27-32.
17. Xarelto [ package insert]. http://www.xareltohcp.com/xareltoprescribing- information.html?utm-campaign5Branded%20-%20Phrase&utm-source 5google&utm-medium5cpc&utm-content5Site%20Link&utm- term5Site%20Link%20Prescribing%20Information. Accessed August 2, 2011.
18. Khemasuwan D, Suramaethakul N. Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. Clin Appl Thromb Hemost. 2012 ; 18 (5): 476-486.
19. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol. 2006 ; 46 (9): 981-990.
20. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006 ; 46 (5): 549-558.
21. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007 ; 47 (2): 218-226
22. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010 ; 113 (3): 726-745.
23. Jiménez D, Yusen RD, Ramacciotti E. Apixaban: an oral direct factor-xa inhibitor. Adv Ther. 2012 ; 29 (3): 187-201.
24. Roser-Jones C, Becker RC. Apixaban: an emerging oral factor Xa inhibitor. J Thromb Thrombolysis. 2010 ; 29 (1): 141-146.
25. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012 ; 172 (5): 397-402.
26. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res. 2011 ; 127 (suppl 2): S5-S12.
27. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011 ; 31 (3): 326-343.
28. Alexander JH, Lopes RD, James S, et al ; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 ; 365 (8): 699-708.
29. Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost. 2012 ; 38 (1): 7-15.
30. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012 ;107(5):985-997.
31. Samama MM, Contant G, Spiro TE, et al ; Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost. 2012 ; 18 (2): 150-158.
32. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost. 2012 ; 38 (2): 178-184.
33. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors [published online ahead of print April 2, 2012]. Clin Appl Thromb Hemost. doi:10.1177/1076029612441859.
34. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011 ; 32 (3): 267-271.
35. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012 ; 10 (2): 160-163.
36. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012 ; 119 (9): 2172-2174.
37. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012 ; 116 (5): 1093-1096.
38. Kulik A, Saltzman MB, Morris JJ. Dabigatran after cardiac surgery: caution advised. J Thorac Cardiovasc Surg. 2011 ; 142 (5): 1288.
39. Truumees E, Gaudu T, Dieterichs C, Geck M, Stokes J. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine. 2012 ;37(14): E863-865.
40. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate- A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 ; 103 (6): 1116-1127.
41. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011 ; 7 (4): 281-287.
42. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011 ; 42 (12): 3594-3599.
43. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation. 2011 ; 124 (14): 1573-1579.
44. Bauer KA. Reversal of antithrombotic agents. A m J Hematol. 2012 ; 87 (suppl 1): S119-S126.
45. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010 ; 49 (4): 259-268.
46. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012 ; 87 (suppl 1): S141-S145.
47. Schulman SCM, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012 ; 119 (13): 3016-3023.
48. Connolly SJ, Ezekowitz MD, Yusuf S, et al ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151.
49. Eriksson BI, Dahl OE, Huo MH, et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011 ; 105 (4): 721-729.
50. Eriksson BI, Dahl OE, Rosencher N, et al ; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 ; 5 (11): 2178-2185.
51. Eriksson BI, Dahl OE, Rosencher N, et al ; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 ; 370 (9591): 949-956.
52. Ginsberg JS, Davidson BL, Comp PC, et al; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 ; 24 (1): 1-9.
53. Beasley BNUE, Unger EF, Temple R. Anticoagulant options- why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011 ; 364 (19): 1788-1790.
54. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM ; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 ; 363 (26): 2487-2498.
55. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P ; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 ; 375 (9717): 807-815.
56. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 ; 361 (6): 594-604.
57. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al ; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 ; 365 (23): 2167-2177
58. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. NCT00643201. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2008. http://clinicaltrials.gov/ct2/show/ NCT00643201. Updated August 16, 2012. Accessed December 27 2012.
59. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. NCT00633893. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2008. http://clinicaltrials.gov/show/ NCT00633893. Updated November 6, 2012. Accessed December 27, 2012.
60. Connolly SJ, Eikelboom J, Joyner C, et al ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 ; 364 (9): 806-817.
61. Granger CB, Alexander JH, McMurray JJ, et al ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 (11):981-992.
62. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thrombopro-phylaxis after hip arthroplasty. N Engl J Med. 2008 ; 358 (26):2765-2775.
63. Kakkar AK, Brenner B, Dahl OE, et al ; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 ; 372 (9632): 31-39.
64. Lassen MR, Ageno W, Borris LC, et al ; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26): 2776-2786.
65. Turpie AG, Lassen MR, Davidson BL, et al ; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 ; 373 (9676): 1673-1680.
66. Cohen AT, Spiro TE, Büller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011 ; 31 (4): 407-416.
67. Bauersachs R, Berkowitz SD, Brenner B, et al ; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 ; 363 (26): 2499-2510.
68. Ramualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continuation treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther. 2011 ; 7 (9): 841-844.
69. Büller HR, Prins MH, Lensin AW, et al ; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 ; 366 (14): 1287-1297.
70. Patel MR, Mahaffey KW, Garg J, et al ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 (10): 883-891.
71. Schulman S, Kearon C, Kakkar AK, et al ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 ; 361 (24): 2342-2352.
72. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 ; 100 (9): 1419-1426.
73. Oldgren J, Budaj A, Granger CB, et al ; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, doubleblind, phase II trial. Eur Heart J. 2011 ; 32 (22): 2781-2789.
74. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012; 125(5): 669-676.
75. You JJ, Singer DE, Howard PA, et al ; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2): e531S-e575S.
76. Kearon C, Akl EA, Comerota AJ, et al ; American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(suppl 2): e419S- e494S.
77. Rivaroxaban compares favorably with enoxaparin in preventing venous thromboembolism in acutely ill patients without showing a net clinical benefit. American College of Cardiology website. http://www.cardiosource.org/ News-Media/Media-Center/News-Releases/2011/04/MAGELLAN.aspx. 2011. Accessed December 27, 2012.
78. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 ; 32 (19): 2387-2394.
79. Buller H, Deitchman D, Prins M, Segers A ; Botticelli Investigators, Writing Committe. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008 ; 6 (8): 1313-1318.
80. Falck-Ytter Y, Francis CW, Johanson NA, et al ; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2): e278S-e325S.
81. Gould MK, Garcia DA, Wren SM, et al ; American College of Chest Physicians. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2): e227S-e277S.
82. Kahn SR, Lim W, Dunn AS, et al; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (suppl 2): e195S-e226S.
83. DeLoughery TG. Practical aspects of the oral new anticoagulants. Am J Hematol. 2011 ; 86 (7): 586-590.
84. Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis. 2010 ; 29 (2): 182-191.